139 related articles for article (PubMed ID: 36272467)
21. Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.
Zhu L; Zhang X; Lei N; Liu W; Miao Z; Zhuang C; Sheng C; Guo W; Dong G; Yao J; Cheng P; Zhang W
Chem Biodivers; 2012 Jun; 9(6):1084-94. PubMed ID: 22700227
[TBL] [Abstract][Full Text] [Related]
22. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Ulivi P; Zoli W; Fabbri F; Brigliadori G; Ricotti L; Tesei A; Rosetti M; De Cesare M; Beretta GL; Corna E; Supino R; Zunino F
Neoplasia; 2005 Feb; 7(2):152-61. PubMed ID: 15802020
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
24. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.
Pisano C; De Cesare M; Beretta GL; Zuco V; Pratesi G; Penco S; Vesci L; Foderà R; Ferrara FF; Guglielmi MB; Carminati P; Dallavalle S; Morini G; Merlini L; Orlandi A; Zunino F
Mol Cancer Ther; 2008 Jul; 7(7):2051-9. PubMed ID: 18645015
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin.
Yang CJ; Li B; Zhang ZJ; Gao JM; Wang MJ; Zhao XB; Song ZL; Liu YQ; Li H; Chen Y; Lee KH; Morris-Natschke SL; Xu C
Eur J Med Chem; 2020 Feb; 187():111971. PubMed ID: 31881457
[TBL] [Abstract][Full Text] [Related]
26. Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study.
Bailly C; Vergoten G
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838813
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
28. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.
Yao L; Zhao X; Li Q; Zu Y; Fu Y; Zu B; Meng X; Liu C
Int J Pharm; 2012 Feb; 423(2):586-8. PubMed ID: 22193057
[TBL] [Abstract][Full Text] [Related]
30. Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo.
Zheng S; Chang S; Lu J; Chen Z; Xie L; Nie Y; He B; Zou S; Gu Z
PLoS One; 2011; 6(6):e21064. PubMed ID: 21695227
[TBL] [Abstract][Full Text] [Related]
31. [Preliminary study of apoptosis of human hepatocarcinoma cell line HepG2 induced by topotecan].
Zhang J; Pu SP; Zhou YJ
Ai Zheng; 2002 Dec; 21(12):1305-9. PubMed ID: 12520736
[TBL] [Abstract][Full Text] [Related]
32. Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma.
Khodair AI; El-Hallouty SM; Cagle-White B; Abdel Aziz MH; Hanafy MK; Mowafy S; Hamdy NM; Kassab SE
Eur J Med Chem; 2024 Feb; 265():116049. PubMed ID: 38185054
[TBL] [Abstract][Full Text] [Related]
33. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
Lian C; Cao S; Zeng W; Li Y; Su J; Li J; Zhao S; Wu L; Tao J; Zhou J; Chen X; Peng C
Biochem Pharmacol; 2020 Jan; 171():113716. PubMed ID: 31751535
[TBL] [Abstract][Full Text] [Related]
34. [Synthesis and antitumor activity of 20-O-linked camptothecin ester derivatives].
Pan XD; Liu HY; Sun PY; Zhu CG; Yang J; Yuan KH; Han R
Yao Xue Xue Bao; 2004 Aug; 39(8):591-7. PubMed ID: 15563058
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Kurtzberg LS; Battle T; Rouleau C; Bagley RG; Agata N; Yao M; Schmid S; Roth S; Crawford J; Krumbholz R; Ewesuedo R; Yu XJ; Wang F; Lavoie EJ; Teicher BA
Mol Cancer Ther; 2008 Oct; 7(10):3212-22. PubMed ID: 18852125
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
Liu W; Zhu L; Guo W; Zhuang C; Zhang Y; Sheng C; Cheng P; Yao J; Wang W; Dong G; Wang S; Miao Z; Zhang W
Eur J Med Chem; 2011 Jun; 46(6):2408-14. PubMed ID: 21463912
[TBL] [Abstract][Full Text] [Related]
37. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
McDonald AC; Brown R
Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
[TBL] [Abstract][Full Text] [Related]
38. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
40. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
